Literature DB >> 12399124

Reduced expression of CD44 v3 and v6 is related to invasion in lung adenocarcinoma.

Hiroaki Suzuki1, Katsushige Yamashiro.   

Abstract

We have previously reported that the histological pattern of invasion is correlated with the prognosis of surgically treated patients of lung adenocarcinoma. On the other hand, several clinicopathologic studies have shown that CD44 variant isoforms are associated with invasion and metastasis in human malignant tumors. The expression of CD44 variant isoforms v3 and v6 was analyzed in 93 Japanese lung adenocarcinoma patients by immunostaining to study the relationship between their expression and the invasion in lung adenocarcinoma. The specimens were histologically categorized into three groups. Both the invasive lesion and the noninvasive lesion were observed in 49 out of 93 cases (group I). Twenty cases were noninvasive carcinoma growing mainly in a lepidic pattern (group II). Twenty-three cases were invasive carcinoma which showed no frankly noninvasive lesion growing in a lepidic pattern (group III). The significant reduced expression of CD44 v3 and v6 was observed in the invasive lesion compared with the noninvasive lesion in adenocarcinoma of group I (P < 0.05). Although reduced expression of CD44 v3 and v6 was observed in the invasive carcinoma of group III compared with the noninvasive carcinoma of group II, it was not significant (P = 0.0693 for v3, P = 0.0827 for v6). The pattern of expression of CD44 v3 was significantly concordant with that of CD44 v6 (P < 0.0001). Our results suggest that reduced expression of CD44 v3 and v6 is associated with the invasion in the lung adenocarcinoma. Copyright 2002 Elsevier Science Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399124     DOI: 10.1016/s0169-5002(02)00176-9

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  7 in total

1.  Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma.

Authors:  Dongrong Situ; Hao Long; Peng Lin; Zhihua Zhu; Jiang Wang; Xu Zhang; Zeming Xie; Tiehua Rong
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-03       Impact factor: 4.553

2.  CD44v6 down-regulation is an independent prognostic factor for poor outcome of colorectal carcinoma.

Authors:  Lili Wang; Qin Liu; Dongliang Lin; Maode Lai
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.

Authors:  Joseph P Connor; Mildred Felder; Arvinder Kapur; Nonyem Onujiogu
Journal:  BMC Cancer       Date:  2012-05-14       Impact factor: 4.430

4.  Aerosol delivery of small hairpin osteopontin blocks pulmonary metastasis of breast cancer in mice.

Authors:  Kyeong-Nam Yu; Arash Minai-Tehrani; Seung-Hee Chang; Soon-Kyung Hwang; Seong-Ho Hong; Ji-Eun Kim; Ji-Young Shin; Sung-Jin Park; Ji-Hye Kim; Jung-Taek Kwon; Hu-Lin Jiang; Bitna Kang; Duyeol Kim; Chan-Hee Chae; Kee-Ho Lee; Tae-Jong Yoon; George R Beck; Myung-Haing Cho
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

5.  Expression analysis of CD44 isoforms S and V3, in patients with esophageal squamous cell carcinoma.

Authors:  Atena Mansouri; Ali Mohammad Foroughmand; Mohammad Reza Abbaszadegan; Bahram Memar; Reihaneh Alsadat Mahmoudian; Mehran Gholamin
Journal:  Iran J Basic Med Sci       Date:  2015-04       Impact factor: 2.699

Review 6.  Novel CD44-downstream signaling pathways mediating breast tumor invasion.

Authors:  Allal Ouhtit; Balsam Rizeq; Haissam Abou Saleh; Md Mizanur Rahman; Hatem Zayed
Journal:  Int J Biol Sci       Date:  2018-10-05       Impact factor: 6.580

7.  Demonstration of a melanoma-specific CD44 alternative splicing pattern that remains qualitatively stable, but shows quantitative changes during tumour progression.

Authors:  Livia Raso-Barnett; Balazs Banky; Tamas Barbai; Peter Becsagh; Jozsef Timar; Erzsebet Raso
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.